COSMOS Pharmaceutical Balance Sheet Health
Financial Health criteria checks 4/6
COSMOS Pharmaceutical has a total shareholder equity of ¥237.2B and total debt of ¥26.8B, which brings its debt-to-equity ratio to 11.3%. Its total assets and total liabilities are ¥485.0B and ¥247.8B respectively. COSMOS Pharmaceutical's EBIT is ¥33.6B making its interest coverage ratio 395.7. It has cash and short-term investments of ¥51.4B.
Key information
11.3%
Debt to equity ratio
JP¥26.82b
Debt
| Interest coverage ratio | 395.7x |
| Cash | JP¥51.42b |
| Equity | JP¥237.20b |
| Total liabilities | JP¥247.83b |
| Total assets | JP¥485.03b |
Recent financial health updates
We Think COSMOS Pharmaceutical (TSE:3349) Can Stay On Top Of Its Debt
Sep 26
We Think COSMOS Pharmaceutical (TSE:3349) Can Stay On Top Of Its Debt
Jun 10Recent updates
COSMOS Pharmaceutical's (TSE:3349) Returns On Capital Not Reflecting Well On The Business
Nov 18We Think COSMOS Pharmaceutical (TSE:3349) Can Stay On Top Of Its Debt
Sep 26An Intrinsic Calculation For COSMOS Pharmaceutical Corporation (TSE:3349) Suggests It's 41% Undervalued
Aug 17COSMOS Pharmaceutical (TSE:3349) Will Want To Turn Around Its Return Trends
Aug 01Subdued Growth No Barrier To COSMOS Pharmaceutical Corporation's (TSE:3349) Price
Jun 28We Think COSMOS Pharmaceutical (TSE:3349) Can Stay On Top Of Its Debt
Jun 10COSMOS Pharmaceutical Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Apr 17Some Shareholders Feeling Restless Over COSMOS Pharmaceutical Corporation's (TSE:3349) P/E Ratio
Mar 16Returns On Capital At COSMOS Pharmaceutical (TSE:3349) Paint A Concerning Picture
Feb 28Financial Position Analysis
Short Term Liabilities: 3349's short term assets (¥156.4B) do not cover its short term liabilities (¥216.8B).
Long Term Liabilities: 3349's short term assets (¥156.4B) exceed its long term liabilities (¥31.0B).
Debt to Equity History and Analysis
Debt Level: 3349 has more cash than its total debt.
Reducing Debt: 3349's debt to equity ratio has increased from 6.3% to 11.3% over the past 5 years.
Debt Coverage: 3349's debt is well covered by operating cash flow (205.7%).
Interest Coverage: 3349's interest payments on its debt are well covered by EBIT (395.7x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 04:54 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/08/31 |
| Annual Earnings | 2024/05/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
COSMOS Pharmaceutical Corporation is covered by 20 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Arashi Nishizawa | BofA Global Research |
| Mitsuru Takayanagi | Citigroup Inc |
| Jun Kawahara | Daiwa Securities Co. Ltd. |